Phatlhane DV, Zemlin AE

Language: English
References: 15
Page: 924-928
PDF size: 134.09 Kb.

ABSTRACT

Lipoprotein X (LpX) is an abnormal lipoprotein associated with cholestasis. It is a significant cause of severe hypercholesterolemia and should always be considered in patients with cholestatic liver disease. This case highlights the significance of LpX as a cause of severe hypercholesterolemia in a patient with cholestasis secondary to a granulomatous hepatitis attributed to tuberculosis. Lipoprotein agarose gel electrophoresis and gradient gel electrophoresis were performed for the detection of LpX. The liver function tests, electrolytes, lipid profile and bile acids were also determined. Anti-tuberculous therapy was initiated and the liver functions improved with normalisation of the lipid profile.

REFERENCES

1. Seidel D, Alaupovic P, Furman RH. A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects. J Clin Invest 1969; 48: 1211-23.

2. Ross A, Murphy GM, Wilkinson PA, Mills GL, Sherlock S. Occurrence of an abnormal lipoprotein in patients with liver disease. Gut 1970; 11: 1035-7.

3. Seidel D, Buff HU, Fauser U, Bleyl U. On the metabolism of lipoprotein-X (LP-X). Clin Chim Acta 1976; 66: 195-207.

4. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008; 337: 503-8.

5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90.

6. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25: 541-51.

7. Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant 2005; 35: 85-9.

8. Zidan H, Lo S, Wiebe D, Talano J, Alemzadeh R. Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver. Pediatr Blood Cancer 2008; 50: 1280-1.

9. Yon JL, Anuras S, Wu K, Forker EL. Granulomatous hepatitis, increased platelet aggregation, and hypercholesterolaemia. Ann Intern Med 1976; 84(2): 148-50.

10. Walli AK, Seidel D. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein- X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. J Clin Invest 1984; 74: 867-79.

11. Le Riche M, Burgess LJ, Marais AD. Pseudohyponatraemia in a patient with obstructive jaundice. Clin Chim Acta 2006; 366: 357-60.

12. Sivakumar T, Chaidarun S, Lee HK, Cervinski M, Comi R. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer. J Clin Lipidol 2011; 5: 324-8.

13. Fei H, Maeda S, Kirii H, Fujigaki S, Maekawa N, Fujii H, Wada H, et al. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum. Clin Chem 2000; 46: 1351-6.

14. Chang P-Y, Lu S-C, Su T-C, Chou S-F, Huang W-H, Morrisett JD, Chen C-H, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-22.

15. Crook MA. Lipoprotein X: clinical implications. Ann Clin Biochem 2013; 50: 93-4.